Search alternatives:
values decrease » values increased (Expand Search), largest decrease (Expand Search)
marked decrease » marked increase (Expand Search)
0 decrease » _ decrease (Expand Search), a decrease (Expand Search), 026 decrease (Expand Search)
Showing 1 - 20 results of 4,877 for search '(( ct ((values decrease) OR (marked decrease)) ) OR ( 22 ((0 decrease) OR (mean decrease)) ))', query time: 0.38s Refine Results
  1. 1
    Decreased cytokine expression in J2.2-HKU1.7b-infected BMDM.

    Decreased cytokine expression in J2.2-HKU1.7b-infected BMDM. by Chaminda D. Gunawardene (22794593)

    Published 2025
    Save to List
    Saved in:
  2. 2
    Boxplot comparing Ct values for HD in flies and clothes.

    Boxplot comparing Ct values for HD in flies and clothes. by Philippe Ndzomo (17706039)

    Published 2025
    Save to List
    Saved in:
  3. 3
    RipAF1 interferes with the activity of NbFNR and decreases the ATP accumulation.

    RipAF1 interferes with the activity of NbFNR and decreases the ATP accumulation. by Lihaitian Wang (22530602)

    Published 2025
    Save to List
    Saved in:
  4. 4
    Lymphocytes decreased in mouse pneumonia model.

    Lymphocytes decreased in mouse pneumonia model. by Qi Xu (134661)

    Published 2025
    Save to List
    Saved in:
  5. 5
    B2 decreases glycolytic intermediates in cells.

    B2 decreases glycolytic intermediates in cells. by Craig Eyster (392633)

    Published 2025
    Save to List
    Saved in:
  6. 6
    Mean observer DCCR (%) and DDR (%) at C2-3 in neutral (n = 22) and flexed (n = 18) neck positions.

    Mean observer DCCR (%) and DDR (%) at C2-3 in neutral (n = 22) and flexed (n = 18) neck positions. by Devon England (21262225)

    Published 2025
    Save to List
    Saved in:
  7. 7
    Thermoneutrality decreased sepsis survival.

    Thermoneutrality decreased sepsis survival. by Goldia Chan (21453340)

    Published 2025
    Save to List
    Saved in:
  8. 8
    Repetitive stress induces a decrease in sound-evoked activity.

    Repetitive stress induces a decrease in sound-evoked activity. by Ghattas Bisharat (20706928)

    Published 2025
    Save to List
    Saved in:
  9. 9
    Overview of the six original ACTIV-3/TICO trials.

    Overview of the six original ACTIV-3/TICO trials. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  10. 10
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  11. 11
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  12. 12
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  13. 13
    Antibody and antigen responses to Ensovibep vs placebo day 1–90.

    Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  14. 14
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  15. 15
    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis).

    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  16. 16
    Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments).

    Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  17. 17
    Long-term anti-nucleocapsid response by baseline patient characteristics.

    Long-term anti-nucleocapsid response by baseline patient characteristics. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  18. 18
    Antibody and antigen responses to Lufotrelvir vs placebo day 1–90.

    Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  19. 19
    Baseline patient characteristics across neutralizing monoclonal antibody trials.

    Baseline patient characteristics across neutralizing monoclonal antibody trials. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  20. 20
    Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies.

    Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:

Search Tools: